Thermo Fisher Scientific (NYSE:TMO) Price Target Raised to $650.00

Key Points

• Analysts at JPMorgan Chase & Co. have raised the price target for Thermo Fisher Scientific from $600 to $650, indicating a potential upside of 21.32% from its previous close.
• Currently, 16 analysts rate Thermo Fisher Scientific with a "Buy," while 6 analysts issued a "Hold," resulting in a consensus target price of $593.43.
• In its most recent quarterly earnings, Thermo Fisher reported $5.36 earnings per share, exceeding the consensus estimate of $5.22, and posted a revenue of $10.86 billion.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) had its price objective boosted by analysts at JPMorgan Chase & Co. from $600.00 to $650.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an "overweight" rating on the medical research company's stock. JPMorgan Chase & Co.'s price target would suggest a potential upside of 21.32% from the company's previous close.

TMO has been the subject of a number of other reports. Redburn Partners set a $580.00 price target on Thermo Fisher Scientific in a research note on Wednesday. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Weiss Ratings reiterated a "hold (c-)" rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, October 4th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus target price of $593.43.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $0.43 on Thursday, hitting $535.76. 89,981 shares of the company's stock were exchanged, compared to its average volume of 2,425,933. The stock has a 50-day moving average of $486.09 and a 200-day moving average of $448.21. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $610.97. The stock has a market cap of $202.31 billion, a price-to-earnings ratio of 30.99, a P/E/G ratio of 2.93 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period in the prior year, the company earned $5.37 earnings per share. The company's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts expect that Thermo Fisher Scientific will post 23.28 earnings per share for the current year.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Large investors have recently added to or reduced their stakes in the business. CBIZ Investment Advisory Services LLC lifted its position in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares in the last quarter. Anderson Financial Strategies LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $30,000. Capital A Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 825.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock worth $30,000 after buying an additional 66 shares in the last quarter. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $31,000. Finally, DiNuzzo Private Wealth Inc. lifted its position in shares of Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock worth $31,000 after buying an additional 61 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.